In contrast to Castera et al. who found mutations in RAD51C/RAD51D/BRIP1 dominantly in French OC patients with a positive family OC history [32], we identified mutations in these genes in 1/116 (0.9%) and 22/587 (3.7%) carriers in HOC patients and in patients with a negative family cancer history, respectively. This evidence concerns the gene RAD51D and cancer.